FDA Approves First Oral Antiviral Drug for COVID-19
The FDA has granted full approval to nirmatrelvir-ritonavir (Paxlovid) for treating adult outpatients with mild to moderate COVID-19 who are at risk for severe disease, the agency announced on Thursday. “Today’s approval demonstrates that Paxlovid has met the agency’s rigorous standards for safety and effectiveness, and that it remains an important treatment option for people […]
Paxlovid May Lower Long COVID Risk, VA Study Suggests
Use of nirmatrelvir-ritonavir (Paxlovid) in older adults with risk factors for severe disease was associated with a roughly 25% lower risk of a post-COVID condition (PCC), a retrospective study of Veterans Affairs data showed. In the cohort of over 280,000 patients with a confirmed COVID case, 13% of those prescribed nirmatrelvir-ritonavir went on to develop […]
FDA Panel Backs Full Approval of Paxlovid for COVID-19
An FDA panel recommended the agency grant full approval to nirmatrelvir-ritonavir (Paxlovid) for treating high-risk COVID-19. By a vote of 16-1 on Thursday, the Antimicrobial Drugs Advisory Committee said the totality of evidence supports the traditional approval of the oral antiviral, which has been widely used since late 2021 under an emergency use authorization to […]
Can Paxlovid, Molnupiravir Benefit Hospitalized COVID Patients Too?
During the Omicron BA.2 wave, antivirals molnupiravir and nirmatrelvir-ritonavir (Paxlovid) appeared to have clinical benefit in hospitalized patients with mild-to-moderate COVID-19 who did not require oxygen therapy, a retrospective cohort study from Hong Kong showed. For patients who were treated with the antivirals within 2 days of hospitalization, a 52% and 66% lower risk of […]